Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931...
Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.
Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.
...
Johns Hopkins University, Baltimore, Maryland, United States
Stratton VA Medical Center, Albany, New York, United States
Hortense and Louis Rubin Dialysis Center, Troy, New York, United States
New York Presbyterian Hospital, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
VA Medical Center, Salem, Virginia, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.